866-997-4948(US-Canada Toll Free)

Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market

Published By :

GBI Research

Published Date : Oct 2011

Category :

Ophthalmology

No. of Pages : 156 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market, which provides insights into the global ophthalmology therapeutics market forecast until 2017. The report provides an in-depth analysis of the six therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. 

The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indication. In addition, the report includes insights into the ophthalmology R&D pipeline. GBI Research analysis shows that the overall global ophthalmology market for glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration was valued at $10.3 billion in 2010. 

The market is expected to grow at a CAGR of 3.6% for the forecast period and will reach $13.2 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report also examines global ophthalmology treatment usage patterns and includes insights into the ophthalmology therapeutics R&D product pipeline.

The top pharmaceutical companies in ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these above six companies.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration therapeutics market.
  • Data and analysis for the global ophthalmology therapeutics market
  • Annualized market data for the ophthalmology therapeutics market from 2002 to 2010, with forecasts to 2017
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the global ophthalmology therapeutics market
  • Key M&A activities and Licensing Agreements that took place in the ophthalmology therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

  • Align your product portfolio to the markets with high growth potential.
  • Develop market entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of the ophthalmology market.
  • Develop key strategic initiatives by understanding the key focus areas and leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1.1 List of Tables 7
1.2 List of Figures 10

2 Global Ophthalmology Market - Introduction 12
2.1 Overview 12
2.2 GBI Research Report Guidance 12

3 Global Ophthalmology Market - Market Characterization 13
3.1 Introduction 13
3.2 Revenue Forecast for the Global Ophthalmology Market 13
3.2.1 Revenues 13
3.2.2 Annual Cost of Treatment (ACT) 15
3.3 Branded and Generic Market Share 17
3.4 Treatment Usage Patterns 18
3.4.1 Diseased Population 20
3.4.2 Treatment Seeking Population 21
3.4.3 Diagnosed Population 22
3.4.4 Prescription Population 23

4 Global Ophthalmology Market - Geographical Landscape 24
4.1 The US 24
4.1.1 Revenue 24
4.1.2 Annual Cost of Treatment 25
4.1.3 Treatment Usage Pattern 26
4.2 Top Five European Countries 28
4.2.1 Revenues of the Top Five European Countries 28
4.2.2 Annual Cost of Treatment 30
4.2.3 Treatment Usage Pattern 31
4.3 Japan 33
4.3.1 Revenues 33
4.3.2 Annual Cost of Treatment 34
4.3.3 Treatment Usage Pattern 35

5 Global Ophthalmology Market - Glaucoma Therapeutics Market 37
5.1 Introduction 37
5.2 Global Market Forecasts 38
5.3 Annual Cost of Treatment 40
5.4 Branded and Generic Market Share 41
5.5 Treatment Flow Algorithm 42
5.6 Treatment Usage Patterns 43
5.7 Market Forecasts for The US 46
5.8 Market Forecasts for the Top Five European Countries 47
5.9 Market Forecasts for Japan 48
5.10 Drivers of the Glaucoma Market 49
5.10.1 Increasing Prevalence of Eye Diseases 49
5.10.2 Improved Diagnosis of the Disease 49
5.11 Restraints for Glaucoma Market 49
5.11.1 Lower Awareness and Treatment Seeking Rates 49
5.11.2 Patent Expiry of Major Glaucoma Drugs such as Xalatan and Alphagan will Result in Negative Growth 49

6 Global Ophthalmology Market - Allergic Conjunctivitis 50
6.1 Introduction 50
6.1.1 Seasonal Allergic Conjunctivitis (SAC) 50
6.1.2 Perennial Allergic Conjunctivitis (PAC) 50
6.2 Market Forecasts 51
6.3 Annual Cost of Treatment 52
6.4 Branded and Generic Market Share 53
6.5 Treatment Flow Algorithm 54
6.6 Treatment Usage Patterns 55
6.7 Market Forecasts for the US 57
6.8 Market Forecasts for the Top Five European Countries 58
6.9 Market Forecasts for Japan 59
6.10 Drivers of Allergic Conjunctivitis Market 60
6.10.1 Increasing Awareness 60
6.11 Restraints for Allergic Conjunctivitis Market 60
6.11.1 Series of Patent Expires will Result in Slower Market Growth 60

7 Global Ophthalmology Market - Wet Age Macular Degeneration 61
7.1 Introduction 61
7.2 Global Market Forecasts 61
7.3 Annual Cost of Treatment 63
7.4 Branded and Generic Market Share 64
7.5 Treatment Flow Algorithm 65
7.6 Treatment Usage Patterns 66
7.7 Market Forecasts for the US 69
7.8 Market Forecasts for the Top Five European Countries 70
7.9 Market Forecasts for Japan 72
7.10 Drivers of Macular Degeneration Market 73
7.10.1 Elderly Population to Drive Macular Degeneration Population 73
7.10.2 Active Research and Development Efforts will Drive Market 73
7.10.3 Improvements in Diagnostic Tools will Increase the Diagnosed Population 73
7.11 Restraints for Macular Degeneration Market 73
7.11.1 Extremely Poor Treatment Seeking Rates Especially for Wet Macular Degeneration will Result in Very Small Potential Customer Segment 73
7.11.2 Increasing Off Label Use of Cheaper Drugs will Impact Annual Cost of Therapy 73

8 Global Ophthalmology Market - Diabetic Macular Edema 74
8.1 Introduction 74
8.2 Global Market Forecasts 74
8.3 Annual Cost of Treatment 76
8.4 Branded and Generic Market Share 77
8.5 Treatment Flow Algorithm 78
8.6 Treatment Usage Patterns 79
8.7 Market Forecasts for The US 81
8.8 Market Forecasts for the Top Five European Countries 82
8.9 Market Forecasts for Japan 83
8.10 Drivers of the Diabetic Macular Edema Market 84
8.10.1 Increasing Prevalence of Conditions Such as Diabetes will Drive the Market 84
8.10.2 Improved Awareness will Drive Volumes 84
8.11 Restraints for Macular Edema Market 84
8.11.1 Availability of Effective Alternative Options Such as Laser Treatment 84

9 Global Ophthalmology Market - Dry Eye Syndrome 85
9.1 Introduction 85
9.2 Global Market Forecasts 85
9.3 Annual Cost of Treatment 86
9.4 Branded and Generic Market Share 87
9.5 Treatment Flow Algorithm 88
9.6 Treatment Usage Patterns 89
9.7 Market Forecasts for the US 90
9.8 Market Forecasts for the Top Five European Countries 91
9.9 Market Forecasts for Japan 92
9.10 Drivers for the DES Therapeutics Market 93
9.10.1 Increase in Prevalence 93
9.11 Barriers for the DES Therapeutics Market 93
9.11.1 Low Treatment Seeking Rate 93
9.11.2 Inadequate Treatment Options 93

10 Global Ophthalmology Market - Diabetic Retinopathy 94
10.1 Introduction 94
10.2 Global Market Forecasts 94
10.3 Annual Cost of Treatment 96
10.4 Branded and Generic Market Share 97
10.5 Treatment Flow Algorithm 98
10.6 Treatment Usage Patterns 99
10.7 Market Forecasts for The US 101
10.8 Market Forecasts for the Top Five European Countries 102
10.9 Market Forecasts for Japan 103
10.10 Drivers for the DR Therapeutics Market 104
10.10.1 Diabetic Population Growth 104
10.10.2 Advancement of Innovative Targeted Therapies 104
10.11 Barriers for the DR Therapeutics Market 104
10.11.1 Low Prescription Rates 104
10.11.2 Late Stage Diagnosis 104

11 Global Ophthalmology Market - Pipeline Analysis 105
11.1 Introduction 105
11.2 Glaucoma - Research and Development Pipeline 106
11.2.1 Overview 106
11.2.2 Pipeline by Clinical Phases of Development 107
11.3 Diabetic Macular Edema - Research and Development Pipeline 110
11.3.1 Overview 110
11.3.2 Pipeline by Clinical Phases of Development 111
11.4 Wet Aged Macular Degeneration - Research and Development Pipeline 113
11.4.1 Overview 113
11.4.2 Pipeline by Clinical Phases of Development 114
11.5 Allergic Conjunctivitis - Research and Development Pipeline 118
11.5.1 Overview 118
11.5.2 Pipeline by Clinical Phases of Development 119
11.6 Dry Eye Syndrome - Research and Development Pipeline 121
11.6.1 Overview 121
11.6.2 Pipeline by Clinical Phases of Development 122
11.7 Diabetic Retinopathy - Research and Development Pipeline 125
11.7.1 Overview 125
11.7.2 Pipeline by Clinical Phases of Development 126

12 Profiles of Promising Drugs in Ophthalmology Therapeutics Market 128
12.1 Glaucoma 128
12.1.1 Tafluprost (Saflutan) 128
12.1.2 NCX-116 (Formerly PF-03187207) 129
12.2 Diabetic Macular Edema 129
12.2.1 Macugen (Pegaptanib Sodium) 129
12.2.2 Iluvien (Fluocinolone Acetonide) 130
12.2.3 iCo-007 131
12.3 Wet Age Macular Degeneration 131
12.3.1 VEGF Trap-Eye 131
12.4 Allergic Conjunctivitis 131
12.4.1 SCH 697243 131
12.4.2 Grass Pollen Allergoid 132
12.4.3 SAR 1118 132
12.5 Dry Eye Syndrome 133
12.5.1 Rebamipide (OPC-12759E) 133
12.5.2 CF101 133
12.5.3 Remura (Bromfenac) 134
12.5.4 Tasocitinib (CP-690550) 134
12.6 Diabetic Retinopathy 134
12.6.1 Lucentis (Ranibizumab) 134
12.6.2 Macugen (Pegaptanib Sodium) 135
12.6.3 Arxxant (Ruboxistaurin) 135
12.6.4 Vitreosolve 136
12.6.5 Nevanac (Nepafenac Ophthalmic) 137

13 Global Ophthalmology Market - Competitive Landscape 138
13.1 Company Profiles for Ophthalmology 138
13.1.1 Pfizer 138
13.1.2 Allergan, Inc. 138
13.1.3 Alcon, Inc. 139
13.1.4 Novartis AG 140
13.1.5 Merck & Co Inc 141
13.1.6 Roche 142

14 Global Ophthalmology Market - Strategic Consolidations 144
14.1 Mergers and Acquisitions 144
14.1.1 Overview 144
14.1.2 Major Mergers and Acquisitions Deals 144
14.1.3 Segmentation by Geography 144
14.1.4 Segmentation by Deal Value 146
14.2 Co-development Deals 147
14.2.1 Major Co-development Deals 147
14.2.2 Segmentation by Geography 147
14.3 Licensing Deals 148
14.3.1 Major Licensing Deals 148
14.3.2 Segmentation by Geography 148
14.3.3 Segmentation by Value 149

15 Global Ophthalmology Therapeutics Market - Appendix 150
15.1 Market Definitions 150
15.2 Abbreviations 150
15.3 Research Methodology 150
15.3.1 Coverage 151
15.3.2 Secondary Research 151
15.3.3 Primary Research 151
15.4 Therapeutic Landscape 152
15.4.2 Market Size by Geography 154
15.5 Geographical Landscape 155
15.6 Pipeline Analysis 155
15.7 Competitive Landscape 155
15.7.1 Expert Panel Validation 155
15.8 Contact Us 155
15.9 Disclaimer 155
15.10 Sources 156

List of Table


Table 1: Ophthalmology Market, Global, Revenues, ($bn), 2002-2010
Table 2: Ophthalmology Market, Global, Revenues, ($bn), 2010-2017
Table 3: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2002-2010
Table 4: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2010-2017
Table 5: Ophthalmology Market, Global, Treatment Usage Patterns, (million), 2002-2010
Table 6: Ophthalmology Market, Global, Treatment Usage Patterns, (million), 2010-2017
Table 7: Ophthalmology Market, The US, Revenues, ($m), 2002-2010
Table 8: Ophthalmology Market, The US, Revenues, ($m), 2010-2017
Table 9: Ophthalmology Market, The US, Annual Cost of Treatment, ($), 2002-2010
Table 10: Ophthalmology Market, The US, Annual Cost of Treatment, ($), 2010-2017
Table 11: Ophthalmology Market, The US, Treatment Usage Patterns, (million), 2002-2010
Table 12: Ophthalmology Market, The US, Treatment Usage Patterns, (million), 2010-2017
Table 13: Ophthalmology Market, Top Five European Countries, Revenues, ($bn), 2002-2010
Table 14: Ophthalmology Market, Top Five European Countries, Revenues, ($bn), 2010-2017
Table 15: Ophthalmology Market, Top Five European Countries, ACT, ($), 2002-2010
Table 16: Ophthalmology Market, Top Five European Countries, ACT, ($), 2010-2017
Table 17: Ophthalmology Market, Top Five European Countries, Treatment Usage Patterns, (million), 2002-2010
Table 18: Ophthalmology Market, Top Five European Countries, Treatment Usage Patterns, (million), 2010-2017
Table 19: Ophthalmology Market, Japan, Revenues, ($m), 2002-2010
Table 20: Ophthalmology Market, Japan, Revenues, ($m), 2010-2017
Table 21: Ophthalmology Market, Japan, Annual Cost of Treatment, ($), 2002-2010
Table 22: Ophthalmology Market, Japan, Annual Cost of Treatment, ($), 2010-2017
Table 23: Ophthalmology Market, Japan, Treatment Usage Patterns, (million), 2002-2010
Table 24: Ophthalmology Market, Japan, Treatment Usage Patterns, (million), 2010-2017
Table 25: Glaucoma Market, Global, Revenues, ($bn), 2002-2010
Table 26: Glaucoma Market, Global, Revenues, ($bn), 2010 - 2017
Table 27: Glaucoma Market, Global, Annual Cost of Treatment, ($), 2002-2010
Table 28: Glaucoma Market, Global, Annual Cost of Treatment, ($), 2010-2017
Table 29: Glaucoma Market, Global, Treatment Usage Patterns, (million), 2002-2010
Table 30: Glaucoma Market, Global, Treatment Usage Patterns, (million), 2010-2017
Table 31: Glaucoma Market, The US, Revenues, ($m), 2002-2010
Table 32: Glaucoma Market, The US, Revenues, ($m), 2010-2017
Table 33: Glaucoma Market, Top Five European Countries, Revenues, ($m), 2002-2010
Table 34: Glaucoma Market, Top Five European Countries, Revenues, ($m), 2010-2017
Table 35: Glaucoma Market, Japan, Revenues, ($m), 2002-2010
Table 36: Glaucoma Market, Japan, Revenues, ($m), 2010-2017
Table 37: Allergic Conjunctivitis, Global, Revenues, ($m), 2002-2010
Table 38: Allergic Conjunctivitis, Global, Revenues, ($m), 2010-2017
Table 39: Allergic Conjunctivitis, Global, Annual Cost of Treatment, ($), 2002-2010
Table 40: Allergic Conjunctivitis, Global, Annual Cost of Treatment, ($), 2010-2017
Table 41: Allergic Conjunctivitis, Global, Treatment Usage Patterns, (million), 2002-2010
Table 42: Allergic Conjunctivitis, Global, Treatment Usage Patterns, (million), 2010-2017
Table 43: Allergic Conjunctivitis, The US, Revenues, ($m), 2002-2010
Table 44: Allergic Conjunctivitis, The US, Revenues, ($m), 2010-2017
Table 45: Allergic Conjunctivitis, Top Five European Countries, Revenues, ($m), 2002-2010
Table 46: Allergic Conjunctivitis, Top Five European Countries, Revenues, ($m), 2010-2017
Table 47: Allergic Conjunctivitis, Japan, Revenues, ($m), 2002-2010
Table 48: Allergic Conjunctivitis, Japan, Revenues, ($m), 2010-2017
Table 49: Wet Age Macular Degeneration, Global, Revenues, ($m), 2002-2010
Table 50: Wet Age Macular Degeneration, Global, Revenues, ($m), 2010-2017
Table 51: Wet Age Macular Degeneration, Global, Annual Cost of Treatment, ($), 2002-2010
Table 52: Wet Age Macular Degeneration, Global, Annual Cost of Treatment, ($), 2010-2017
Table 53: Wet Age Macular Degeneration, Global, Treatment Usage Patterns, (000\'), 2002-2010
Table 54: Wet Age Macular Degeneration, Global, Treatment Usage Patterns, (000\'), 2010-2017
Table 55: Wet Age Macular Degeneration, The US, Revenues, ($m), 2002-2010
Table 56: Wet Age Macular Degeneration, The US, Revenues, ($m), 2010-2017
Table 57: Wet Age Macular Degeneration, Top Five European Countries, Revenues, ($m), 2002-2010
Table 58: Wet Age Macular Degeneration, Top Five European Countries, Revenues, ($m), 2010-2017
Table 59: Wet Age Macular Degeneration, Japan, Revenues, ($m), 2002-2010
Table 60: Wet Age Macular Degeneration, Japan, Revenues, ($m), 2010-2017
Table 61: Diabetic Macular Edema, Global, Revenues, ($m), 2002-2010
Table 62: Diabetic Macular Edema, Global, Revenues, ($m), 2010-2017
Table 63: Diabetic Macular Edema, Global, Annual Cost of Treatment, ($), 2002-2010
Table 64: Diabetic Macular Edema, Global, Annual Cost of Treatment, ($), 2010-2017
Table 65: Diabetic Macular Edema, Global, Treatment Usage Patterns, (000\'), 2002-2010
Table 66: Diabetic Macular Edema, Global, Treatment Usage Patterns, (000\'), 2010-2017
Table 67: Diabetic Macular Edema, The US, Revenues, ($m), 2002-2010
Table 68: Diabetic Macular Edema, The US, Revenues, ($m), 2010-2017
Table 69: Diabetic Macular Edema, Top Five European Countries, Revenues, ($m), 2002-2010
Table 70: Diabetic Macular Edema, Top Five European Countries, Revenues, ($m), 2010-2017
Table 71: Diabetic Macular Edema, Japan, Revenues, ($m), 2002-2010
Table 72: Diabetic Macular Edema, Japan, Revenues, ($m), 2010-2017
Table 73: Dry Eye Syndrome, Global, Revenues, ($m), 2002-2010
Table 74: Dry Eye Syndrome, Global, Revenues, ($m), 2010-2017
Table 75: Dry Eye Syndrome, Global, Annual Cost of Treatment, ($), 2002-2010
Table 76: Dry Eye Syndrome, Global, Annual Cost of Treatment, ($), 2010-2017
Table 77: Dry Eye Syndrome, Global, Treatment Usage Patterns, (million), 2002-2010
Table 78: Dry Eye Syndrome, Global, Treatment Usage Patterns, (million), 2010-2017
Table 79: Dry Eye Syndrome, The US, Revenues, ($m), 2002-2010
Table 80: Dry Eye Syndrome, The US, Revenues, ($m), 2010-2017
Table 81: Dry Eye Syndrome, Top Five European Countries, Revenues, ($m), 2002-2010
Table 82: Dry Eye Syndrome, Top Five European Countries, Revenues, ($m), 2010-2017
Table 83: Dry Eye Syndrome, Japan, Revenues, ($m), 2002-2010
Table 84: Dry Eye Syndrome, Japan, Revenues, ($m), 2010-2017
Table 85: Diabetic Retinopathy, Global, Revenues, ($m), 2002-2010
Table 86: Diabetic Retinopathy, Global, Revenues, ($m), 2010-2017
Table 87: Diabetic Retinopathy, Global, Annual Cost of Treatment, ($), 2002-2010
Table 88: Diabetic Retinopathy, Global, Annual Cost of Treatment, ($), 2010-2017
Table 89: Diabetic Retinopathy, Global, Treatment Usage Patterns, (millions), 2002-2010
Table 90: Diabetic Retinopathy, Global, Treatment Usage Patterns, (millions), 2010-2017
Table 91: Diabetic Retinopathy, The US, Revenues, ($m), 2002-2010
Table 92: Diabetic Retinopathy, The US, Revenues, ($m), 2010-2017
Table 93: Diabetic Retinopathy, Top Five European Countries, Revenues, ($m), 2002-2010
Table 94: Diabetic Retinopathy, Top Five European Countries, Revenues, ($m), 2010-2017
Table 95: Diabetic Retinopathy, Japan, Revenues, ($m), 2002-2010
Table 96: Diabetic Retinopathy, Japan, Revenues, ($m), 2010-2017
Table 97: Ophthalmology Market, Global, Number of Molecules in Pipeline, 2011
Table 98: Glaucoma Market, Global, Pipeline Molecules by Phase, 2011
Table 99: Glaucoma Market, Global, Pre-clinical/Discovery Pipeline Molecules, 2011
Table 100: Glaucoma Market, Global, Phase l Pipeline Molecules, 2011
Table 101: Glaucoma Market, Global, Phase ll Pipeline Molecules, 2011
Table 102: Glaucoma Market, Global, Phase lll Pipeline Molecules, 2011
Table 103: Glaucoma Market, Global, NDA Filed Molecules, 2011
Table 104: Diabetic Macular Edema, Global, Pipeline Molecules by Phase, 2011
Table 105: Diabetic Macular Edema, Global, Number of Pre-clinical/Discovery Pipeline Molecules, 2011
Table 106: Diabetic Macular Edema, Global, Number of Phase l Pipeline Molecules, 2011
Table 107: Diabetic Macular Edema, Global, Number of Phase ll Pipeline Molecules, 2011
Table 108: Diabetic Macular Edema, Global, Number of Phase lll Pipeline Molecules, 2011
Table 109: Diabetic Macular Edema, Global, Number of NDA Filed Molecules, 2011
Table 110: Wet Age Macular Degeneration, Pipeline Molecules by Phase, 2011
Table 111: Wet Age Macular Degeneration, Number of Pre-clinical/Discovery Molecules, 2011
Table 112: Wet Age Macular Degeneration, Number of Phase l Molecules, 2011
Table 113: Wet Age Macular Degeneration, Number of Phase ll Molecules, 2011
Table 114: Wet Age Macular Degeneration, Number of Phase lll Molecules, 2011
Table 115: Allergic Conjunctivitis, Global, Pipeline Molecules by Phase, 2011
Table 116: Allergic Conjunctivitis, Global, Number of Pre-clinical/Discovery Molecules, 2011
Table 117: Allergic Conjunctivitis, Global, Number of Phase ll Molecules, 2011
Table 118: Allergic Conjunctivitis, Global, Number of Phase lll Molecules, 2011
Table 119: Allergic Conjunctivitis, Global, Number of NDA Filed Molecules, 2011
Table 120: Dry Eye Syndrome, Global, Pipeline Molecules by Phase, 2011
Table 121: Dry Eye Syndrome, Global, Number of Pre-clinical/Discovery Molecules, 2011
Table 122: Dry Eye Syndrome, Global, Number of Phase l Molecules, 2011
Table 123: Dry Eye Syndrome, Global, Number of Phase ll Molecules, 2011
Table 124: Dry Eye Syndrome, Global, Number of Phase lll Molecules, 2011
Table 125: Dry Eye Syndrome, Global, Number of NDA Filed Molecules, 2011
Table 126: Diabetic Retinopathy, Global, Pipeline Molecules by Phase, 2011
Table 127: Diabetic Retinopathy, Global, Number of Pre-clinical/Discovery Molecules, 2011
Table 128: Diabetic Retinopathy, Global, Number of Phase l Molecules, 2011
Table 129: Diabetic Retinopathy, Global, Number of Phase ll Molecules, 2011
Table 130: Diabetic Retinopathy, Global, Number of Phase lll Molecules, 2011
Table 131: Diabetic Retinopathy, Global, Number of NDA Filed Molecules, 2011
Table 132: Ophthalmology Market, Global, Number of Deals by Geography, 2011
Table 133: Ophthalmology Market, Global, Number of Deals by Deal Value, ($m), 2011
Table 134: Ophthalmology Market, Global, Number of Deals by Geography, 2011
Table 135: Ophthalmology Market, Global, Number of Deals by Geography, 2011
Table 136: Ophthalmology Market, Global, Number of Deals by Deal Value, ($m), 2011

List of Chart


Figure 1: Ophthalmology Market, Global, Revenues, ($bn), 2002-2017 13
Figure 2: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2002-2017 15
Figure 3: Ophthalmology Market, Global, Branded and Generic Market Share, (%), 2010-2017 17
Figure 4: Ophthalmology Market, Global, Treatment Usage Patterns, (million), 2002-2017 18
Figure 5: Ophthalmology Market, Global, Diseased Population, (million), 2002-2017 20
Figure 6: Ophthalmology Market, Global, Treatment Seeking Population, (million), 2002-2017 21
Figure 7: Ophthalmology Market, Global, Diagnosed Population, (million), 2002-2017 22
Figure 8: Ophthalmology Market, Global, Prescription Population, (million), 2002-2017 23
Figure 9: Ophthalmology Market, The US, Revenues, ($m), 2002-2017 24
Figure 10: Ophthalmology Market, The US, Annual Cost of Treatment, ($), 2002-2017 25
Figure 11: Ophthalmology Market, The US, Treatment Usage Patterns, (million), 2002-2017 26
Figure 12: Ophthalmology Market, Top Five European Countries, Revenues, ($bn), 2002-2017 28
Figure 13: Ophthalmology Market, Top Five European Countries, ACT, ($), 2002-2017 30
Figure 14: Ophthalmology Market, Top Five European Countries, Treatment Usage Patterns, (million), 2002-2017 31
Figure 15: Ophthalmology Market, Japan, Revenues, ($m), 2002-2017 33
Figure 16: Ophthalmology Market, Japan, Annual Cost of Treatment, ($), 2002-2017 34
Figure 17: Ophthalmology Market, Japan, Treatment Usage Patterns, (million), 2002-2017 35
Figure 18: Glaucoma Market, Global, Revenues, ($m), 2002-2017 38
Figure 19: Glaucoma Market, Global, Annual Cost of Treatment, ($), 2002-2017 40
Figure 20: Glaucoma Market, Global, Branded and Generic Market Share, (%), 2010-2017 41
Figure 21: Glaucoma Market, Global, Treatment Flow Algorithm 42
Figure 22: Glaucoma Market, Global, Treatment Usage Patterns, (million), 2002-2017 43
Figure 23: Glaucoma Market, The US, Revenues, ($m), 2002-2017 46
Figure 24: Glaucoma Market, Top Five European Countries, Revenues, ($m), 2002-2017 47
Figure 25: Glaucoma Market, Japan, Revenues, ($m), 2002-2017 48
Figure 26: Allergic Conjunctivitis, Global, Revenues, ($m), 2002-2017 51
Figure 27: Allergic Conjunctivitis, Global, Annual Cost of Treatment, ($), 2002-2017 52
Figure 28: Allergic Conjunctivitis, Global, Branded and Generic Market Share, (%), 2010-2017 53
Figure 29: Allergic Conjunctivitis, Global, Treatment Flow Algorithm, 2011 54
Figure 30: Allergic Conjunctivitis, Global, Treatment Usage Patterns, (million), 2002-2017 55
Figure 31: Allergic Conjunctivitis, The US, Revenues, ($m), 2002-2017 57
Figure 32: Allergic Conjunctivitis, Top Five European Countries, Revenues, ($m), 2002-2017 58
Figure 33: Allergic Conjunctivitis, Japan, Revenues, ($m), 2002-2017 59
Figure 34: Wet Age Macular Degeneration, Global, Revenues, ($m), 2002-2017 61
Figure 35: Wet Age Macular Degeneration, Global, Annual Cost of Treatment, ($), 2002-2017 63
Figure 36: Wet Age Macular Degeneration, Global, Branded and Generic Market Share, (%), 2010-2017 64
Figure 37: Wet Age Macular Degeneration, Global, Treatment Flow Algorithm, 2011 65
Figure 38: Wet Age Macular Degeneration, Global, Treatment Usage Patterns, (million), 2002-2017 66
Figure 39: Wet Age Macular Degeneration, The US, Revenues, ($m), 2002-2017 69
Figure 40: Wet Age Macular Degeneration, Top Five European Countries, Revenues, ($m), 2002-2017 70
Figure 41: Wet Age Macular Degeneration, Japan, Revenues, ($m), 2002-2017 72
Figure 42: Diabetic Macular Edema, Global, Revenues, ($m), 2002-2017 74
Figure 43: Diabetic Macular Edema, Global, Annual Cost of Treatment, ($), 2002-2017 76
Figure 44: Diabetic Macular Edema, Global, Branded and Generic Market Share, (%), 2010-2017 77
Figure 45: Diabetic Macular Edema, Global, Treatment Flow Algorithm, 2011 78
Figure 46: Diabetic Macular Edema, Global, Treatment Usage Patterns, (million), 2002-2017 79
Figure 47: Diabetic Macular Edema, The US, Revenues, ($m), 2002-2017 81
Figure 48: Diabetic Macular Edema, Top Five European Countries, Revenues, ($m), 2002-2017 82
Figure 49: Diabetic Macular Edema, Japan, Revenues, ($m), 2002-2017 83
Figure 50: Dry Eye Syndrome, Global, Revenues, ($m), 2002-2017 85
Figure 51: Dry Eye Syndrome, Global, Annual Cost of Treatment, ($), 2002-2017 86
Figure 52: Dry Eye Syndrome, Global, Branded and Generic Market Share, (%), 2010-2017 87
Figure 53: Dry Eye Syndrome, Global, Treatment Flow Algorithm, 2011 88
Figure 54: Dry Eye Syndrome, Global, Treatment Usage Patterns, (million), 2002-2017 89
Figure 55: Dry Eye Syndrome, The US, Revenues, ($m), 2002-2017 90
Figure 56: Dry Eye Syndrome, Top Five European Countries, Revenues, ($m), 2002-2017 91
Figure 57: Dry Eye Syndrome, Japan, Revenues, ($m), 2002-2017 92
Figure 58: Diabetic Retinopathy, Global, Revenues, ($m), 2002-2017 94
Figure 59: Diabetic Retinopathy, Global, Annual Cost of Treatment, ($), 2002-2017 96
Figure 60: Diabetic Retinopathy, Global, Branded and Generic Market Share, (%), 2010-2017 97
Figure 61: Diabetic Retinopathy Market, Global, Treatment Flow Algorithm, 2011 98
Figure 62: Diabetic Retinopathy, Global, Treatment Usage Patterns, (millions), 2002-2017 99
Figure 63: Diabetic Retinopathy, The US, Revenues, ($m), 2002-2017 101
Figure 64: Diabetic Retinopathy, Top Five European Countries, Revenues, ($m), 2002-2017 102
Figure 65: Diabetic Retinopathy, Japan, Revenues, ($m), 2002-2017 103
Figure 66: Ophthalmology Market, Global, Pipeline Analysis, (%), 2011 105
Figure 67: Glaucoma Market, Global, Pipeline Molecules by Phase, (%), 2011 106
Figure 68: Diabetic Macular Edema, Global, Pipeline Molecules by Phase, (%), 2011 110
Figure 69: Wet Age Macular Degeneration, Pipeline Molecules by Phase, (%), 2011 113
Figure 70: Allergic Conjunctivitis, Global, Pipeline Molecules by Phase, (%), 2011 118
Figure 71: Dry Eye Syndrome, Global, Pipeline Molecules by Phase, (%), 2011 121
Figure 72: Diabetic Retinopathy, Global, Pipeline Molecules by Phase, (%), 2011 125
Figure 73: Pfizer, SWOT, 2011 138
Figure 74: Allergan, SWOT, 2011 139
Figure 75: Alcon Inc, SWOT, 2011 140
Figure 76: Novartis AG, SWOT, 2011 141
Figure 77: Merck Co & Inc, SWOT, 2011 142
Figure 78: Roche, SWOT, 2011 143
Figure 79: Ophthalmology Market, Global, Number of Deals by Geography, (%), 2011 144
Figure 80: Ophthalmology Market, Global, Segmentation of Deals by Value, (%), 2011 146
Figure 81: Ophthalmology Market, Global, Number of Deals by Geography, (%), 2011 147
Figure 82: Ophthalmology Market, Global, Number of Deals by Geography, (%), 2011 148
Figure 83: Ophthalmology Market, Global, Number of Deals by Deal Value, (%), 2011 149
Figure 84: GBI Research Market Forecasting Model 154

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *
  • I agree to receive other communications from Researchmoz, and allow Researchmoz to store and process my personal data.*